Fader Amanda Nickles, Arriba Lucybeth Nieves, Frasure Heidi E, von Gruenigen Vivian E
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Gynecol Oncol. 2009 Jul;114(1):121-7. doi: 10.1016/j.ygyno.2009.03.039. Epub 2009 Apr 29.
Endometrial cancer is the most common gynecologic malignancy in the Western world and is strongly associated with obesity. Despite the fact that most cases are diagnosed in early, more favorable stages, endometrial cancer incidence and mortality rates are on the rise. Morbidly obese women with endometrial cancer are more likely to die of their co-morbidities and also of their cancers when compared to their leaner cohorts. Given the increasing rates of morbid obesity in the United States, it is essential to develop appropriate screening tools and guidelines to reduce cancer morbidity and death amongst this group. Through an analysis of the existing literature, we present a review of the epidemiologic trends in obesity and endometrial cancer, discuss the promising role of screening biomarker studies, review prevention efforts and modifiable risk factors, and ways in which health outcomes and quality of life for endometrial cancer survivors may be optimized.
子宫内膜癌是西方世界最常见的妇科恶性肿瘤,且与肥胖密切相关。尽管大多数病例在早期、预后较好的阶段被诊断出来,但子宫内膜癌的发病率和死亡率仍在上升。与较瘦的患者群体相比,患有子宫内膜癌的病态肥胖女性更有可能死于其合并症以及癌症。鉴于美国病态肥胖率不断上升,开发适当的筛查工具和指南以降低该群体的癌症发病率和死亡率至关重要。通过对现有文献的分析,我们综述了肥胖与子宫内膜癌的流行病学趋势,讨论了筛查生物标志物研究的潜在作用,回顾了预防措施和可改变的风险因素,以及优化子宫内膜癌幸存者健康结局和生活质量的方法。